Treated Diagnoses

Tumor, congenital and very rare diseases

In the IHBT we deal with hematopoietic disorders in their whole variety. Thus, our care covers congenital or acquired non-tumor diseases (anemias, coagulation disorders, etc.), as well as tumor diseases such as leukemia or myelodysplastic syndrome. Moreover, a number of diagnoses we treat is very rare. That means that in the whole Czech Republic they affect perhaps several dozens of people only.

This is why therapies are governed strictly by international and national protocols. At the same time, we often include patients in suitable clinical studies, if they are available.

Therapy often involves several cycles of chemotherapy, targeted biological treatment, immunological, immunosuppressive and instrument treatment (TPE and depletion procedures performed in cooperation with the IHBT Apheresis Department), as well as different forms of hematopoietic stem cell transplantation.)

The most frequent diagnoses:

Acute myeloid leukemia (AML) and lymphoblastic leukemia (ALL)

• The number of newly diagnosed and intensively treated patients in the Inpatient Department is approximately 40 a year. The average age of these patients is 20–68 years
• In 84 percent of patients we usually reach a decline or remission of the disease after two cycles of chemotherapy
• Approximately 20 to 30 percent of these patients have to be earmarked for a bone marrow transplant in the same year

Myelodysplastic syndrome

• Patients with myelodysplastic syndrome (MDS) are treated depending on their age, disease subtype, clinical condition and prognostic score in a conservative way (supportive treatment, chelation, growth factors, immunosuppressives, hypomethylating and immunomodulatory agents) or intensively with combined chemotherapy with a subsequent allogeneic hematopoietic stem cell transplantation
• The disease occurrence increases for persons over 60 years of age, the incidence is 4.5 patients per 100 thousand inhabitants

Chronic myeloid leukemia (CML)

• This disease accounts to 20 to 25 percent of all leukemias in adults and the number of newly identified cases is 1 to 1.5 per 100 thousand inhabitants a year
• Every year our centre diagnoses approximately 30 patients; at present we treat almost 400 patients
• The very efficient targeted treatment with the so-called tyrosine kinase inhibitors (TKIs) considerably improved their prognosis, restores a full-fledged life to patients and, in fact, it does not shorten the length of their lives

Hemophilia

• This most frequent type of coagulation disorders affects approximately a thousand persons in the Czech Republic
• Usual treatment is performed on a day-case basis by administering the missing coagulation factor
• The number of bleedings are being significantly reduced thank to a modern treatment

Other treated diagnoses:

• Myeloproliferative disease
• Chronic lymphocytic or lymphatic leukemia
• Severe cases of hemolytic anemia, aplastic anemia
• Complications related to the provided treatment (infections, virus reactivation, graft reaction against the host)